Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Imipenem antagonism of the in vitro activity of piperacillin against Pseudomonas aeruginosa.

Literature DB >> 6435517

Imipenem antagonism of the in vitro activity of piperacillin against Pseudomonas aeruginosa.

Abstract

The MICs of imipenem and piperacillin, alone and in combination, against Pseudomonas aeruginosa were determined in a checkerboard titration microdilution assay. A dramatic, one-way antagonism of imipenem for piperacillin was demonstrated in 28 of the 35 strains examined; antagonism was associated with the induction of a beta-lactamase.

Entities: Chemical Species

Mesh：

Substances：

Year: 1984 PMID： 6435517 PMCID： PMC284137 DOI： 10.1128/AAC.26.2.272

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

16 in total

1. Simplified, accurate method for antibiotic assay of clinical specimens.

Authors: J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal: Appl Microbiol Date: 1966-03

2. Piperacillin therapy for serious bacterial infections.

Authors: D J Winston; W Murphy; L S Young; W L Hewitt
Journal: Am J Med Date: 1980-08 Impact factor: 4.965

3. Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method.

Authors: H O Hallander; K Dornbusch; L Gezelius; K Jacobson; I Karlsson
Journal: Antimicrob Agents Chemother Date: 1982-11 Impact factor: 5.191

4. Comparative evaluation of piperacillin in vitro.

Authors: G M Dickinson; T J Cleary; T A Hoffman
Journal: Antimicrob Agents Chemother Date: 1978-12 Impact factor: 5.191

5. Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability.

Authors: H C Neu; P Labthavikul
Journal: Antimicrob Agents Chemother Date: 1982-01 Impact factor: 5.191

6. Piperacillin (T-1220), a new semisynthetic penicillin. II. In vitro antimicrobial activity and synergy comparison with carbenicillin and gentamicin.

Authors: R N Jones; R R Packer; A L Barry; R E Badal; C Thornsberry; C Baker
Journal: J Antibiot (Tokyo) Date: 1979-01 Impact factor: 2.649

7. Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties.

Authors: J S Kahan; F M Kahan; R Goegelman; S A Currie; M Jackson; E O Stapley; T W Miller; A K Miller; D Hendlin; S Mochales; S Hernandez; H B Woodruff; J Birnbaum
Journal: J Antibiot (Tokyo) Date: 1979-01 Impact factor: 2.649

8. Clinical trial of piperacillin with acquisition of resistance by Pseudomonas and clinical relapse.

Authors: G L Simon; D R Snydman; F P Tally; S L Gorbach
Journal: Antimicrob Agents Chemother Date: 1980-07 Impact factor: 5.191

9. Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

Authors: C H O'Callaghan; A Morris; S M Kirby; A H Shingler
Journal: Antimicrob Agents Chemother Date: 1972-04 Impact factor: 5.191

10. MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities.

Authors: H Kropp; J G Sundelof; J S Kahan; F M Kahan; J Birnbaum
Journal: Antimicrob Agents Chemother Date: 1980-06 Impact factor: 5.191

11 in total

1. In vitro activity of imipenem against enterococci and staphylococci and evidence for high rates of synergism with teicoplanin, fosfomycin, and rifampin.

Authors: E Debbia; P E Varaldo; G C Schito
Journal: Antimicrob Agents Chemother Date: 1986-11 Impact factor: 5.191

2. In vitro activity of BMY-28142 against pediatric pathogens, including isolates from cystic fibrosis sputum.

Authors: D A Conrad; R K Scribner; A H Weber; M I Marks
Journal: Antimicrob Agents Chemother Date: 1985-07 Impact factor: 5.191

3. Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin against Pseudomonas aeruginosa and other bacterial pathogens.

Authors: C I Bustamante; G L Drusano; R C Wharton; J C Wade
Journal: Antimicrob Agents Chemother Date: 1987-04 Impact factor: 5.191

Review 4. [A comparative review of combination therapy: 2 beta-lactams versus beta-lactam plus aminoglycoside].

Authors: P Dejace; J Klastersky
Journal: Infection Date: 1987 Impact factor: 3.553

Review 5. In vitro activity of imipenem--a review.

Authors: I Braveny
Journal: Eur J Clin Microbiol Date: 1984-10 Impact factor: 3.267

Review 6. Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors: S P Clissold; P A Todd; D M Campoli-Richards
Journal: Drugs Date: 1987-03 Impact factor: 9.546

Review 7. Antibacterial therapy in patients with malignancies.

Authors: K H Mayer; S M Opal
Journal: Cancer Metastasis Rev Date: 1987 Impact factor: 9.264

8. Comprehensive evaluation of ciprofloxacin-aminoglycoside combinations against Enterobacteriaceae and Pseudomonas aeruginosa strains.

Authors: I Haller
Journal: Antimicrob Agents Chemother Date: 1985-11 Impact factor: 5.191

9. Imipenem-induced resistance to antipseudomonal beta-lactams in Pseudomonas aeruginosa.

Authors: F Tausk; M E Evans; L S Patterson; C F Federspiel; C W Stratton
Journal: Antimicrob Agents Chemother Date: 1985-07 Impact factor: 5.191

10. Imipenem and meropenem induced resistance to beta-lactam antibiotics in Pseudomonas aeruginosa.

Authors: A Giacometti; F M Siquini; O Cirioni; S Petroni; G Scalise
Journal: Eur J Clin Microbiol Infect Dis Date: 1994-04 Impact factor: 3.267